Endocrinology and nuclear medicine aspects of the treatment of thyroid tumours

Česká verzia

Authors: P. Vlček
Authors place of work: Klinika nukleární medicíny a endokrinologie 2. lékařské fakulty UK a FN Motol, Praha, přednosta doc. MUDr. Petr Vlček, CSc.
Published in the journal: Vnitř Lék 2007; 53(7-8): 807-811
Category:

Summary

Thyroid tumours belong among the most frequent malignant tumours in endocrinology. The rate of incidence of new carcinomas has increased dramatically in recent years; the rate of thyroid tumour incidence, in particular of its less advanced papillary forms, sextupled in the Czech Republic in the previous decade. The article brings an overview of the factors involved in the development of thyroid tumours, and the classification and clinical assessment of their different types. Recombinant human TSH has started to be used in the Czech Republic as part of preparation of patients for radioiodine treatment. Also discussed is the relevance of tumour markers for the prognosis of the disease in the context of life-long monitoring of patients with thyroid carcinoma.

Key words:
thyroid carcinoma – radioiodine – recombinant TSH – microtumour – prognosis

Zdroje

1. Miller B, Kolonel LN, Bernstein L et al. Radical/ethnic patterns of cancer in the United States 1988-1992. Cancer Institute NIH Pub 1996, No. 96-4104.

2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United Stattes, 1972-2002. JAMA 2006; 295: 2164-2167.

3. Pacini F, Vorontsova T, Demidchik EP et al. Post-Chernobyl thyroid carcinoma in Belarus chlidren and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997; 82: 3563-3569.

4. Němec J et al. Pokroky v diagnostice a léčbě nemocí štítné žlázy. 1. ed. Praha: Avicenum 1975.

5. Sarlis NJ. Thyroid Cancer in Childhood. In: Mazzaferri EL, Hamer C, Mallick UK. Practical Management of Thyroid Cancer. London: Springer-Verlag 2006: 303-320.

6. Block MA, Jackson CE, Greenawald KA et al. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg 1980; 115: 142-148.

7. Jindřichová Š, Vlček P, Bendlová B. Genetické příčiny vzniku karcinomů štítné žlázy. Čas Lék Čes 2004; 143: 664-668.

8. Dvořák J, Neumann J. Chirurgická léčba karcinomu štítné žlázy. Čas Lék Čes 1995; 134: 374-377.

9. Vlček P, Neumann J. Karcinom štítné žlázy, pooperační sledování nemocných. Praha: Maxdorf 2002.

10. Waxmann A, Ramanna L, Chapman N et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation. J Nucl Med 1981; 25: 861-865.

11. Schlumberger M, Mancusi F, Baudin E et al. 131I therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273-276.

12. Schlumberger M, Pacini F. Thyroid tumors. Paris: Nukleon 1999.

13. Mazzaferri E. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6: 469-476.

14. Němec J, Bílek P, Zamrazil V et al. The prognostic value of plasma thyroglobulin at the time of hypothyroidism and the differentiated thyroid cancer. Nuklear Medizin 1995; 34: 154.